CORRESP Filing
PDS Biotechnology Corp (PDSB) (CIK 0001472091)
Date: April 24, 2026 · CIK: 0001472091 · Accession: 0001140361-26-016759
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289942
Letter
Re:
PDS BIOTECHNOLOGY CORPORATION 303A College Road East Princeton, NJ 08540
April 24, 2026
VIA EDGAR
Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards
PDS Biotechnology Corporation
Registration Statement on Form S-3
File No. 333-289942
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, PDS Biotechnology Corporation (the “ Registrant ”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-289942), so that it may become effective at 5:00 p.m. Eastern Time on April 28, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via a telephone call to the staff.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call Patrick O’Malley, Esq. of DLA Piper LLP (US), counsel to the Company, at (206) 839-4831, with any comments or questions regarding the Registration Statement.
Very truly yours,
PDS BIOTECHNOLOGY CORPORATION
Show Raw Text
CORRESP 1 filename1.htm PDS BIOTECHNOLOGY CORPORATION 303A College Road East Princeton, NJ 08540 April 24, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: PDS Biotechnology Corporation Registration Statement on Form S-3 File No. 333-289942 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, PDS Biotechnology Corporation (the “ Registrant ”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-289942), so that it may become effective at 5:00 p.m. Eastern Time on April 28, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via a telephone call to the staff. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please call Patrick O’Malley, Esq. of DLA Piper LLP (US), counsel to the Company, at (206) 839-4831, with any comments or questions regarding the Registration Statement. Very truly yours, PDS BIOTECHNOLOGY CORPORATION By: /s/ Lars Boesgaard Name: Lars Boesgaard Title: Chief Financial Officer cc: Fahd Riaz, Esq., DLA Piper LLP (US) Dylan Caplan, Esq., DLA Piper LLP (US)